Berliner Boersenzeitung - Revolution or mirage? Controversy surrounds new Alzheimer's drugs

EUR -
AED 4.26841
AFN 80.362394
ALL 97.542216
AMD 446.735356
ANG 2.080099
AOA 1065.794205
ARS 1494.414015
AUD 1.776887
AWG 2.092071
AZN 1.980459
BAM 1.954642
BBD 2.348809
BDT 141.226338
BGN 1.956132
BHD 0.43854
BIF 3466.946195
BMD 1.162261
BND 1.493215
BOB 8.038238
BRL 6.486005
BSD 1.163311
BTN 100.147673
BWP 15.618748
BYN 3.807045
BYR 22780.325028
BZD 2.336716
CAD 1.596076
CDF 3354.287055
CHF 0.932807
CLF 0.029182
CLP 1120.296341
CNY 8.342655
CNH 8.346165
COP 4674.330945
CRC 587.052233
CUC 1.162261
CUP 30.799929
CVE 110.199718
CZK 24.634179
DJF 206.947405
DKK 7.463699
DOP 70.258379
DZD 151.514244
EGP 57.439973
ERN 17.433922
ETB 161.636047
FJD 2.620788
FKP 0.864949
GBP 0.866519
GEL 3.150183
GGP 0.864949
GHS 12.127816
GIP 0.864949
GMD 83.106172
GNF 10094.020343
GTQ 8.931709
GYD 243.385819
HKD 9.117884
HNL 30.445964
HRK 7.532663
HTG 152.739518
HUF 398.923459
IDR 18977.696027
ILS 3.902549
IMP 0.864949
INR 100.127437
IQD 1523.897249
IRR 48945.741055
ISK 142.354235
JEP 0.864949
JMD 186.029797
JOD 0.824089
JPY 172.932309
KES 150.300962
KGS 101.640213
KHR 4662.238109
KMF 491.989694
KPW 1046.046309
KRW 1616.942576
KWD 0.355234
KYD 0.969426
KZT 620.152624
LAK 25087.138481
LBP 104232.653
LKR 350.972086
LRD 233.241828
LSL 20.596898
LTL 3.431856
LVL 0.703041
LYD 6.327252
MAD 10.519168
MDL 19.788278
MGA 5176.933206
MKD 61.523554
MMK 2439.678938
MNT 4168.013035
MOP 9.404829
MRU 46.275587
MUR 53.119698
MVR 17.903172
MWK 2017.205016
MXN 21.795313
MYR 4.935007
MZN 74.338683
NAD 20.596898
NGN 1779.387897
NIO 42.814637
NOK 11.840776
NPR 160.236077
NZD 1.948796
OMR 0.446894
PAB 1.163311
PEN 4.140847
PGK 4.817146
PHP 66.377189
PKR 331.310933
PLN 4.244785
PYG 9003.666265
QAR 4.229694
RON 5.072695
RSD 117.080642
RUB 91.265035
RWF 1681.00418
SAR 4.36165
SBD 9.64543
SCR 17.082281
SDG 697.942292
SEK 11.235354
SGD 1.492813
SHP 0.913355
SLE 26.62005
SLL 24372.046713
SOS 664.806172
SRD 43.245469
STD 24056.466061
STN 24.485495
SVC 10.17897
SYP 15112.803405
SZL 20.592801
THB 37.628259
TJS 11.196867
TMT 4.079538
TND 3.419874
TOP 2.722137
TRY 46.897678
TTD 7.897322
TWD 34.181766
TZS 3030.404801
UAH 48.58252
UGX 4168.530579
USD 1.162261
UYU 46.882227
UZS 14725.276806
VES 135.943958
VND 30404.760344
VUV 138.92149
WST 3.080055
XAF 655.568644
XAG 0.030448
XAU 0.000347
XCD 3.14107
XCG 2.096558
XDR 0.815317
XOF 655.568644
XPF 119.331742
YER 280.163552
ZAR 20.584139
ZMK 10461.752209
ZMW 26.785133
ZWL 374.247723
  • CMSC

    0.0900

    22.314

    +0.4%

  • CMSD

    0.0250

    22.285

    +0.11%

  • RBGPF

    0.0000

    69.04

    0%

  • SCS

    0.0400

    10.74

    +0.37%

  • RELX

    0.0300

    53

    +0.06%

  • RIO

    -0.1400

    59.33

    -0.24%

  • GSK

    0.1300

    41.45

    +0.31%

  • NGG

    0.2700

    71.48

    +0.38%

  • BP

    0.1750

    30.4

    +0.58%

  • BTI

    0.7150

    48.215

    +1.48%

  • BCC

    0.7900

    91.02

    +0.87%

  • JRI

    0.0200

    13.13

    +0.15%

  • VOD

    0.0100

    9.85

    +0.1%

  • BCE

    -0.0600

    22.445

    -0.27%

  • RYCEF

    0.1000

    12

    +0.83%

  • AZN

    -0.1200

    73.71

    -0.16%

Revolution or mirage? Controversy surrounds new Alzheimer's drugs
Revolution or mirage? Controversy surrounds new Alzheimer's drugs / Photo: ALAIN JOCARD - AFP/File

Revolution or mirage? Controversy surrounds new Alzheimer's drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

Text size:

For their defenders, the drugs lecanemab and donanemab represent the first real chance to fight the disease after decades of research -- for detractors, they are another disappointment after a long line of costly failures.

"We have turned a corner" thanks to these treatments, British biologist John Hardy, who has been studying Alzheimer's since the 1990s, told AFP.

Rob Howard, a professor of old age psychiatry at University College London, was on the other side.

"I think that the drugs have been used to raise false and unrealistic hopes in people with Alzheimer's disease and their families," he said.

These opposing statements sum up the entrenched positions on the recently introduced drugs for Alzheimer's, the most common form of dementia which millions of people across the world suffer from.

Lecanemab, sold under the name Leqembi, was developed by US pharma firms Biogen and Eisai. Donanemab, developed by pharma giant Eli Lilly, is sold as Kisunla.

The controversy has seen countries take different stances on whether to approve the drugs or not.

The United States gave the green light to lecanemab in 2023, then donanemab earlier this year.

However the European Union rejected lecanemab in July, a bad omen for donanemab's chance of approval.

Last month, the UK steered a middle course, approving the use of lecanemab but not making it available on the state National Health Service.

What no one denies is that the two drugs are the most effective Alzheimer's treatments ever -- but their effectiveness is limited.

Both appear to reduce cognitive decline in patients at the onset of their disease by around 30 percent.

While that may seem high, it represents a relatively small difference over the year-and-a-half period when the studies were carried out.

"The benefits are so tiny as to be practically invisible in an individual patient," Howard said.

- Exorbitant cost -

For critics, there are not enough benefits to outweigh the risks of the drugs, which can sometimes cause brain swelling or bleeding that in rare cases has proved fatal.

And they are very expensive. At the prices being charged by Biogen and Eisai in the United States, lecanemab would cost 133 billion euros ($148 billion) if given to all eligible patients in the EU, according to a 2023 study.

Advocates of the drugs, including many neurologists, believe they can offer patients a few more precious months of autonomy.

They also believe that the effectiveness of the drugs could be multiplied if patients started taking them earlier in the disease's progression. This could soon be more practicable as research on diagnosing Alzheimer's more quickly has recently been making significant strides.

The differing national policies could also mean that poorer patients are left behind.

"We will see rich people going to the US" for the drugs, Hardy said.

The debate can be traced back in part to a seminal 1992 article by Hardy about how the disease actually works.

The article argues that clumps of protein called amyloid plaques -- a constant in the brains of Alzheimer's patients -- are not just one element among others, but the main factor triggering the disease.

Over the decades, many drugs targeting these amyloid plaques were developed, all of which failed -- until lecanemab and donanemab.

- Pressure from families -

The scepticism from some quarters about the new drugs could be because the previous ones were defended and even lauded by some, despite their ineffectiveness.

Christian Guy-Coichard, the head of French organisation Formindep which monitors medical conflicts of interest, accused Alzheimer's groups, researchers and pharmaceutical firms of being too close.

But France Alzheimer deputy director Benoit Durand said that very little of its funding came from Biogen/Eisai or Eli Lilly, instead pointing towards pressure for new treatments from patients' families.

"They don't understand" the EU's decision to turn down a breakthrough new drug, Durand told AFP. He also feared that laboratories could lose interest in Alzheimer's disease due to the setbacks.

Even within the pharmaceutical industry, some admit that past failures have not necessarily helped build trust.

A doctor working for Eli Lilly, who spoke on condition of anonymity, blamed its rival Biogen for overstating the benefits of previous treatment Aduhelm. The drug was controversially approved in the US in 2021 before being withdrawn.

"The Aduhelm studies were a mess," the doctor said.

The aftermath "did a lot of harm and sowed chaos in the discipline", the doctor added, pointing the finger at Biogen.

In response, Biogen told AFP that it was complying with "the principles of scientific research as well as legal and regulatory requirements".

But the Eli Lilly doctor defended the new treatments all the same, urging people to look to the future, not the past.

Like other specialists, he also acknowledged that other mechanisms besides amyloids that could be behind Alzheimer's need to be explored.

Given the disease's complexity, it is unlikely that "single-target treatments will achieve substantially larger effects" than lecanemab and donanemab, a group of experts wrote in the Journal of Prevention of Alzheimer's Disease last month.

But the new drugs are a "critical step" in Alzheimer's treatment, they added.

(Y.Yildiz--BBZ)